30 January 2024 (Tuesday) - Stem Cell Evidence Alert Update

The nice people at the Stem Cell Evidence Alert sent their update today… This is the sort of thing that I keep hearing that I should be reading as CPD… for all that it is rather interesting, it’s not practically improving what I do on a daily basis

ARTICLE OF THE MONTH Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Jodele, S., et al. (2023) Blood [record in progress] PICO SUMMARY +++++ TOP ARTICLES Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. Abadir, E., et al. (2023) Transplantation and Cellular Therapy [record in progress] Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Chichra, A., et al. (2023) International Journal of Hematology [record in progress] . Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway. Gao, X., et al. (2023) Molecular and Cellular Biochemistry [record in progress] Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Gerbitz, A., et al. (2023) Frontiers in Immunology 14:1251593 Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Harbi, S., et al. (2023) Bone Marrow Transplantation [record in progress] Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA. Pang, Y., et al. (2023) iScience 26:108160 Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients. Peterlin, P., et al. (2023) EJHaem 4 (4):1089-1095 Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Strobl, J., et al. (2023) The British Journal of Dermatology [record in progress] Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Yang, L., et al. (2023) Bone Marrow Transplantation [record in progress]